Literature DB >> 7071130

3-Hydroxymethyl antipyrine excretion in urine after an oral dose of antipyrine. A reconsideration of previously published data and synthesis of a pure reference substance.

M Danhof, M W Teunissen, D D Breimer.   

Abstract

Previously published data from this laboratory on the urinary excretion of 3-hydroxymethyl antipyrine (one of the major metabolites of antipyrine in man) have to be reconsidered, because of use of an impure reference substance in the high-pressure liquid chromatographic assay method. Comparison with newly synthesized, pure 3-hydroxymethyl antipyrine has shown that a correction factor of 0.45 needs to be applied to previously published data. Details of the synthesis of the pure reference 3-hydroxymethyl antipyrine are given.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7071130     DOI: 10.1159/000137594

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  8 in total

1.  Interindividual variations in drug disposition. Clinical implications and methods of investigation.

Authors:  D D Breimer
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

Review 2.  Quantifying hepatic function in the presence of liver disease with phenazone (antipyrine) and its metabolites.

Authors:  J V St Peter; W M Awni
Journal:  Clin Pharmacokinet       Date:  1991-01       Impact factor: 6.447

3.  Antipyrine metabolite formation and excretion in patients with chronic renal failure.

Authors:  M W Teunissen; D Kampf; I Roots; N P Vermeulen; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  Influence of cimetidine on steady state concentration and metabolite formation from antipyrine infused with a rectal osmotic mini pump.

Authors:  M W Teunissen; C H Kleinbloesem; L G de Leede; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

5.  Influence of rifampicin treatment on antipyrine clearance and metabolite formation in patients with tuberculosis.

Authors:  M W Teunissen; W Bakker; J E Meerburg-Van der Torren; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

6.  Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis.

Authors:  M W Teunissen; P Spoelstra; C W Koch; B Weeda; W van Duyn; A R Janssens; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

7.  Influence of alaproclate on antipyrine metabolite formation in man.

Authors:  M W Teunissen; A Wahlén; E Vinnars; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

8.  Antipyrine metabolism in patients with disseminated testicular cancer and the influence of cytostatic treatment.

Authors:  M W Teunissen; P H Willemse; D T Sleijfer; W J Sluiter; D D Breimer
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.